CLINICAL INTERPRETATION OF THE RESULTS OF FIBRO-, STEATOSCANNING OF THE LIVER IN CHRONIC HEPATITIS C
Abstract
Background. Imaging of morphological hepatic alteration by fibroscanning is a promising method for diagnosing chronic stages of diffuse liver lesions.
Objective – to present the results of fibro-, steatoscanning in patients with chronic hepatitis C (CHC).
Materials and methods. Pilot (short-term) fibro-, steatoscanning of the liver was performed in 155 patients with CHC on the basis of “Grodno Regional Infectious Clinical Hospital” over the period of June-July 2018. The project was implemented with the support of “DELRUSEUROPEKff.” (France), that provided the equipment to perform the study within the time frame specified. The fibroscan “Ehosensens VCTEFibroscan 502” (France) was used for imaging. The parameters of liver stiffness (fibrosis) - E (kPa) and steatosis (CAP, dB / m) were studied. The probes were used for processing the data (XL, M, MyFibroScan application) as well as various proprietary methods of processing the findings of fibroscanning (P. Nahon et al.; F. Degos et al.; L. Castera et al., C.S. Pavlov et al., N. Afdahl et al.) and steatoscanning (M. Sasso et al.; T. Karlas et al.).
Results. Fibrosis and steatosis of the liver are characteristic attributes of CHC reliably established by the method of fibro-, steatoscanning. The methods of processing the data have different diagnostic value, differ in the frequency of diagnosis of fibrosis stages and steatosis degree. According to various methods of processing the data of fibroscanning, the stage F0-1 is diagnosed in not less than 50% of patients, F2 is established in 15 - 30%, F3 – in 5 - 7%, F4 (cirrhosis) – in 8 - 15%. According to the methods by M. Sasso et al. and T. Karlas et al. steatosis of the liver is not detected (S0) in 37% and 62% of patients, respectively; the first degree of steatosis (S1) was diagnosed in 12-13%, the second (S2) in 34 and 8% (respectively), the third degree (S3) – in 16-20%. The method for assessing steatosis according to M. Sasso et al. is preferable, since it fixes steatosis of all degrees (from S0 to S3) as well as a decrease in the frequency of steatosis as liver fibrosis progresses from F0 to F4. The method by P. Nahon et al. is the most informative one in assessing fibrosis and the most relevant to clinical, laboratory and morphological indicators of fibrosis in patients with CHC.
Conclusion. The introduction of the method of fibro-, steatoscanning into the programs of prophylactic medical examination of the population and patients with CHC will increase life expectancy due to early diagnosis of pre-cirrhotic stages of diffuse liver diseases of any etiology.
References
1. Borsukov AV, Andreev VG, Gelt TD, Gurbatov SN, Demin IJu, Ivanova EV, Kovalev AV, Kozlova EJu, Mamoshin AV, Morozov MV, Romanov SV, Rudenko OV, Ryhtik PI, Safonov DV, Safonova MA, Timashkov IA; Borsukov AV, ed. Jelastografija sdvigovoj volny: analiz klinicheskih primerov. Smolensk: Smolenskaja gorodskaja tipografija; 2017. 376 p. (Russian).
2. Pambrun E, Bouteloup V, de Lédinghen V, Asselineau J, Fraquelli M, Brunetto M, Forns X, Saito H, Nahon P, Pirisi M, Thiébaut R, Perez P. Individual patient data metaanalysis of transient elastography diagnostic accuracy in liver fibrosis assessment of chronic hepatitis C patients (TE IPD Study). Journal of Hepatology. 2009;50(Suppl 1):150. https://doi.org/10.1016/S0168-8278(09)60399-8.
3. Wong GL, Espinosa WZ, Wong VW. Personalized management of cirrhosis by non-invasive tests of liver fibrosis. Clinical and Molecular Hepatology. 2015;21(3):200-211. doi: 10.3350/cmh.2015.21.3.200.
4. Roccarina D, Rosselli M, Genesca J, Tsochatzis EA. Elastography methods for the non-invasive assessment of portal hypertension. Expert Review of Gastroenterology & Hepatology. 2018;12(2):155-164. doi: 10.1080/17474124.2017.1374852.
5. Borsukov AV, ed. Ultrazvukovaja jelastografija: kak delat pravilno [Ultrasound elastography: how to do right]. Smolensk: Smolenskaja gorodskaja tipografija; 2018. 120 p. (Russian).
6. Echosens: the liver company [Internet]. Paris (France): Echosens: the liver company. [Table], Quantifying fibrosis with FibroScan. Available from: fr.zone-secure.net/56337/890880.
7. Nahon P, Kettaneh A, Tengher-Barna I, Ziol M, de Lédinghen V, Douvin C, Marcellin P, Ganne-Carrié N, Trinchet JC, Beaugrand M. Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. Journal of Hepatology. 2008;49(6):1062-1068. doi: 10.1016/j.jhep.2008.08.011.
8. Degos F, Perez P, Roche B, Mahmoudi A, Asselineau J, Voitot H, Bedossa P; FIBROSTIC study group. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: A multicenter prospective study (the FIBROSTIC study). Journal of Hepatology. 2010;53(6):1013-1021. doi: 10.1016/j.jhep.2010.05.035.
9. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Lédinghen V. Prospective comparison of transient elastography, Fibrotest, APRI and liverbiopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343-350. doi: 10.1053/j.gastro.2004.11.018.
10. Pavlov CS, Casazza G, Nikolova D, Tsochatzis E, Burroughs AK, Ivashkin VT, Gluud C. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. Cochrane Database of Systematic Reviews. 2015;1:CD010542. doi: 10.1002/14651858.CD010542.pub2.
11. Afdhal NH, Bacon BR, Patel K, Lawitz EJ, Gordon SC, Nelson DR, Challies TL, Nasser I, Garg J, Wei LJ, McHutchison JG. Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. Clinical Gastroenterology and Hepatology. 2015;13(4):772-779. doi: 10.1016/j.cgh.2014.12.014.
12. Sasso M, Tengher-Barna I, Ziol M, Miette V, Fournier C, Sandrin L, Poupon R, Cardoso AC, Marcellin P, Douvin C, de Ledinghen V, Trinchet JC, Beaugrand M. Novel controlled attenuation parameter for noninvasive assessment of steatosisusing fibroscan, validation in chronic hepatitis C. Journal of Viral Hepatitis. 2012;19(4):244-253. doi: 10.1111/j.1365-2893.2011.01534.x.
13. Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Lédinghen V, Kumar M, Lupsor-Platon M, Han KH, Cardoso AC, Ferraioli G, Chan WK, Wong VW, Myers RP, Chayama K, Friedrich-Rust M, Beaugrand M, Shen F, Hiriart JB, Sarin SK, Badea R, Jung KS, Marcellin P, Filice C, Mahadeva S [et al.]. Individual patient data meta-analysis of controlled attenuation parameter (Cap) technology for assessing steatosis. Journal of Hepatology. 2017;66(5):1022-1030. doi: 10.1016/j. jhep.2016.12. 022.
14. Tsyrkunov VM, Matievskaya NV, Lukashik SP; Tsyrkunov VM, ed. HCV-infekcija [HCV-infection]. Minsk: Asar; 2012. 480 p. (Russian).
15. Tsyrkunov VM, Prokopchik NI, Andreev VP, Kravchuk RI, Chernyak SA. Klinicheskaja morfologija pecheni: fibroz [Clinical morphology of the liver: fibrosis]. Gepatologija I gastrojenterologija [Hepatology and Gastroenterology]. 2018;2(1):39-51. (Russian).
16. Tsyrkunov VM, Andreev VP, Prokopchik NI, Kravchuk RI. Klinicheskaja morfologija pecheni: distrofii [Clinical morphology of liver: dystrophies]. Gepatologija I gastrojenterologija [Hepatology and Gastroenterology]. 2017;1(2):140-152. (Russian).
